EGI
KPTI icon

EAM Global Investors’s Karyopharm Therapeutics KPTI Stock Holding History

EAM Global Investors’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-9,093
Closed -$2.62M – 134
2020
Q1 		$2.62M Buy
9,093
+959
+12% +$265K 1.53% 10
2019
Q4 		$2.34M Buy
+8,134
New +$1.76M 0.94% 31

Other funds holding KPTI

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

EAM Global Investors's KPTI Position: Q2 2020 in Review

EAM Global Investors sold out of Karyopharm Therapeutics (KPTI) in Q2 2020, closing a stake of 9,093 shares — an estimated $2.62M sold.

EAM Global Investors first reported a position in KPTI in Q4 2019 and held it in 2 quarters. The position peaked at $2.62M in Q1 2020. 155 funds tracked by Wall St. Rank hold KPTI as of Q2 2020.

  • EAM Global Investors reported no remaining Karyopharm Therapeutics position as of Q2 2020 after selling out during the quarter.
  • EAM Global Investors sold 9,093 Karyopharm Therapeutics shares in Q2 2020, an estimated $2.62M.
  • EAM Global Investors first reported a position in Karyopharm Therapeutics in Q4 2019 and held it in 2 quarters.
  • EAM Global Investors's Karyopharm Therapeutics position peaked at $2.62M in Q1 2020.
  • 155 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2020.

Based on EAM Global Investors's 13F filing for Q2 2020, filed 13 Aug 2020.